Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 13/20 | 0.70 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.39 |
| ▸ | TACR3 | P29371 | 3/20 | 0.39 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6866661 | 0.82 | TACR1 (0.73) | TACR1TP53ALDH1A1GPBAR1TACR3 | |
| SCHEMBL6862677 | 0.78 | TACR1 (0.65) | TACR1TP53ALDH1A1GPBAR1TACR3 | |
| SCHEMBL1399470 | 0.74 | TACR1 (0.54) | TACR1GPBAR1TACR3 | |
| SCHEMBL5966342 | 0.72 | TACR1 (0.62) | TACR1GPBAR1 | |
| SCHEMBL5741683 | 0.72 | TACR1 (0.64) | TACR1ALDH1A1TACR3 | |
| SCHEMBL5741984 | 0.72 | TACR1 (0.64) | TACR1ALDH1A1TACR3 | |
| SCHEMBL24574910 | 0.70 | ALDH1A1 (0.66) | TACR1TP53ALDH1A1 | |
| SCHEMBL6862826 | 0.70 | TACR1 (0.77) | TACR1GPBAR1 | |
| SCHEMBL6866855 | 0.70 | TACR1 (0.55) | TACR1ALDH1A1GPBAR1 | |
| SCHEMBL6862560 | 0.69 | TACR1 (0.73) | TACR1GPBAR1TACR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1171419-B1 | BIPHENYL DERIVATIVES AS ANTAGONISTS OF THE NEUROKININE-1 RECEPTOR | HOFFMANN LA ROCHE (CH) | 2004-12-29 | — | — | EP | disclosed |
| US-6552088-B2 | 2'-methyl-biphenyl-2-carboxylic acid-(3,5-bis-trifluoromethyl-benzyl)-methyl-amide, for example; treating disease related to neurokinin 1 receptor | HOFFMANN-LA ROCHE INC. | 2003-04-22 | — | — | US | disclosed |
| US-20020040060-A1 | Biphenyl derivatives | BOS MICHAEL (CA) | 2002-04-04 | — | — | US | disclosed |
| EP-1171419-A1 | BIPHENYL DERIVATIVES AS ANTAGONISTS OF THE NEUROKININE-1 RECEPTOR | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-16 | — | — | EP | disclosed |
| US-6291465-B1 | Biphenyl derivatives | HOFFMANN-LA ROCHE INC. | 2001-09-18 | — | — | US | disclosed |
| WO-2000053572-A1 | BIPHENYL DERIVATIVES AS ANTAGONISTS OF THE NEUROKININE-1 RECEPTOR | F. HOFFMANN-LA ROCHE AG (CH) | 2000-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040060-A1 | Biphenyl derivatives | NR1H4, NR1H2, NR1H3 | TACR1 16/4885TP53 3095/4885ALDH1A1 764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.